tryptanthrine has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, W; He, B; Meng, X; Qin, M; Wang, D; Wang, X; Yang, C; Zhang, H; Zhang, Q; Zheng, Q | 1 |
| Deriabin, P; Dezhenkova, L; Gerasimenko, A; Grammatikova, N; Kaluzhny, D; Klimovich, A; Moskovkina, T; Popov, A; Shchekotikhin, A; Stonik, V; Styshova, O; Udovenko, A | 1 |
2 other study(ies) available for tryptanthrine and B16 Melanoma
| Article | Year |
|---|---|
Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; HeLa Cells; Humans; Immunogenic Cell Death; Indoleamine-Pyrrole 2,3,-Dioxygenase; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanocapsules; Neoplasms; Polyesters; Quinazolines; Tumor Burden | 2019 |
Design, synthesis and biomedical evaluation of mostotrin, a new water soluble tryptanthrin derivative.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Female; HCT116 Cells; Humans; K562 Cells; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Quinazolines; Structure-Activity Relationship; Water | 2020 |